Roman Shingarev is a Nephrology physician. OpenAlex indexes 34 publications with 635 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3702 S State St Ste 107
South Salt Lake, UT 841155096
Telephone
801-288-2634Provider last certified this registry record 3 May 2024.
Clinical trials
- Investigation of the Effects of Electronic Cigarettes on Vascular Health
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202513 payments
- Travere Therapeutics, Inc.Program year20252 payments
- Novo Nordisk IncProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
82.6%Angiotensin receptor blocker (ARB)22.4%Losartan Potassium74%Valsartan14%Olmesartan Medoxomil13%Part D<11 patientsCalcium channel blocker13.7%Amlodipine Besylate100%Part D≥26 patients+ 8 more classes in this area
Metabolism & gastrointestinal
12.9%SGLT2 inhibitor12.9%Jardiance78%Farxiga22%Part D<11 patientsMusculoskeletal
4.6%Xanthine oxidase inhibitor4.6%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Validating the anatomical landmark technique for bedside tunneled central venous catheter placement in the medical intensive care unit
The Journal of Vascular Access
2024 - Global hemodialysis vascular access care: Three decades of evolution
The Journal of Vascular Access
2023 - A Case of Thrombotic Microangiopathy (TMA) Secondary to Bevacizumab Followed by Acute Interstitial Nephritis (AIN) Secondary to Nivolumab: A Strong Case for Serial Biopsies
Journal of the American Society of Nephrology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”